We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+7.82%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$968M
AUM Growth
-$1.1B
(-53%)
Cap. Flow
-$1.16B
Cap. Flow
% of AUM
-120.21%
Top 10 Holdings %
Top 10 Hldgs %
41.41%
Holding
89
New
8
Increased
13
Reduced
37
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$40.1M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
+$24.4M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$19.9M |
| 4 |
ADPT
Adeptus Health Inc
ADPT
|
+$10.4M |
| 5 |
Teladoc Health
TDOC
|
+$5.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$112M |
| 2 |
Amgen
AMGN
|
+$102M |
| 3 |
Gilead Sciences
GILD
|
+$102M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$84.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$83.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
26
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $16.4M | 1.69% |
+987,224
| New | +$19.9M |
|
|
SGNT
27
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $15.1M | 1.56% |
1,008,265
-493,031
| -33% | -$6.33M |
|
|
ALDR
28
DELISTED
Alder Biopharmaceuticals
ALDR
| $13.1M | 1.35% |
525,221
-765,932
| -59% | -$20.7M |
|
29
Intuitive Surgical
ISRG
$122B
| $12.7M | 1.32% |
173,466
-36,837
| -18% | -$2.59M |
|
|
NVO
30
Novo Nordisk
NVO
$223B
| $11.6M | 1.2% |
432,350
| – | – |
|
|
NUVA
31
DELISTED
NuVasive, Inc.
NUVA
| $9.93M | 1.03% |
166,300
| – | – |
|
|
ICPT
32
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $7.8M | 0.81% |
54,651
-190,796
| -78% | -$27.8M |
|
33
Molina Healthcare
MOH
$11.7B
| $7.63M | 0.79% |
152,900
+71,900
| +89% | +$3.84M |
|
|
ISEE
34
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.49M | 0.77% |
146,800
-210,306
| -59% | -$10.4M |
|
|
AMSG
35
DELISTED
Amsurg Corp
AMSG
| $7.47M | 0.77% |
96,400
| – | – |
|
|
TMH
36
DELISTED
Team Health Holdings Inc
TMH
| $7.15M | 0.74% |
175,900
-93,100
| -35% | -$4.06M |
|
37
Novavax
NVAX
$1.35B
| $6.63M | 0.68% |
45,615
+24,990
| +121% | +$2.86M |
|
|
WMGI
38
DELISTED
Wright Medical Group Inc
WMGI
| $6.37M | 0.66% |
366,975
+185,040
| +102% | +$3.39M |
|
|
MNTA
39
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $6.2M | 0.64% |
574,040
-106,512
| -16% | -$1.1M |
|
40
Prothena Corp
PRTA
$453M
| $6.11M | 0.63% |
174,746
-223,354
| -56% | -$9.73M |
|
41
Integra LifeSciences
IART
$1.5B
| $4.83M | 0.5% |
121,120
| – | – |
|
|
SCAI
42
DELISTED
Surgical Care Affiliates, Inc.
SCAI
| $4.69M | 0.48% |
98,300
+18,900
| +24% | +$873K |
|
43
PTC Therapeutics
PTCT
$6.52B
| $4.56M | 0.47% |
648,976
-1,966,265
| -75% | -$14.4M |
|
44
Accuray
ARAY
$30.8M
| $4.29M | 0.44% |
825,875
+53,925
| +7% | +$295K |
|
|
ADXS
45
DELISTED
Advaxis Inc
ADXS
| $3.51M | 0.36% |
28,924
-116,010
| -80% | -$14.9M |
|
46
Collegium Pharmaceutical
COLL
$1.17B
| $3.49M | 0.36% |
294,400
| – | – |
|
47
Regenxbio
RGNX
$511M
| $3.38M | 0.35% |
367,541
-312,700
| -46% | -$3.47M |
|
|
ENTL
48
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $2.67M | 0.28% |
146,006
-3,659
| -2% | -$63K |
|
49
uniQure
QURE
$2.77B
| $2.56M | 0.26% |
347,271
-1,080,042
| -76% | -$12.9M |
|
|
XENT
50
DELISTED
Intersect ENT, Inc
XENT
| $2.5M | 0.26% |
193,140
+77,600
| +67% | +$1.21M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q2 2016 Portfolio in Review
As of Q2 2016, Sectoral Asset Management held 89 positions worth $968M, down 53% from $2.07B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Sectoral Asset Management withdrew a net $1.16B in Q2 2016, closing 25 positions and reducing 37 holdings. Its most notable exit was Amgen, an estimated $102M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Pfizer worth $42M.
- Sectoral Asset Management's largest Q2 2016 buy was Pfizer: 1,256,716 shares worth $42M.
- Sectoral Asset Management added most to Abiomed Inc in Q2 2016, an estimated $24.4M increase.
- Sectoral Asset Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $112M.
- Sectoral Asset Management fully exited Amgen in Q2 2016, selling an estimated $102M.
- Sectoral Asset Management's ten largest holdings make up 41% of its $968M portfolio in Q2 2016.
- Sectoral Asset Management opened 8 new positions and closed 25 in Q2 2016.
- Sectoral Asset Management's portfolio value fell 53% quarter-over-quarter to $968M.
Based on Sectoral Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.